PharmTech Poll Results: Outsourced or In-house? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

PharmTech Poll Results: Outsourced or In-house?

The question:

If your company uses contract service providers and manufacturers, which function(s) do you typically keep in-house?

Your responses:

  • Discovery research (1 response)
  • Preclinical animal research
  • ADME-tox work
  • Formulation development (1 response)
  • Process development (1 response)
  • Clincial-scale manufacturing through Phase I
  • Clinical-scale manufacturing through Phase II
  • Clinical-scale manufacturing through Phase III
  • Clinical trials
  • Scale-up to commercial manufacturing (2 responses)
  • Commercial-scale manufacturing (2 responses)
  • Fill-finish
  • Other

Do you have any comments on this poll, or would you like to submit your vote? Email us at


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here